Pfizer and BioNTech have reached an agreement with the European Commission to supply 200 million doses of their candidate coronavirus vaccine to EU member states with the possibility of increasing the contract by another 100 million doses. Deliveries are expected to begin by the end of 2020, subject to positive clinical trial results and regulatory approvals.